Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma

Wagenaar, H; Pecorelli, S; Vergote, Ignace; Curran, D; Wagener, D; Kobierska, A; Bolis, G; ten Bokkel-huinink, W; Lacave, A; Madronal, C; Forni, M; de Oliviera, C; Mangioni, C; Nooij, M; Goupil, A; Kerbrat, P; Marth, C; Tumolo, S; Herben, M; Zanaboni, F; Vermorken, J

Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma

Author:

Wagenaar, H

Pecorelli, S ; Vergote, Ignace ; Curran, D ; Wagener, D ; Kobierska, A ; Bolis, G ; ten Bokkel-huinink, W ; Lacave, A ; Madronal, C ; Forni, M ; de Oliviera, C ; Mangioni, C ; Nooij, M ; Goupil, A ; Kerbrat, P ; Marth, C ; Tumolo, S ; Herben, M ; Zanaboni, F ; Vermorken, J

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Obstetrics & Gynecology, Fallopian tube carcinoma, phase II trial, chemotherapy, cyclophosphamide, adriamycin, cisplatin, RETROSPECTIVE ANALYSIS, CHEMOTHERAPY, ADENOCARCINOMA, DOXORUBICIN, MANAGEMENT, EXPERIENCE, PROGNOSIS, THERAPY, Adenocarcinoma, Aged, Antibiotics, Antineoplastic, Antineoplastic Agents, Alkylating, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Cyclophosphamide, Doxorubicin, Drug Administration Schedule, Europe, Fallopian Tube Neoplasms, Female, Humans, Middle Aged, Neoplasm Staging, Survival Analysis, Treatment Outcome, 1112 Oncology and Carcinogenesis, 1115 Pharmacology and Pharmaceutical Sciences, 1116 Medical Physiology, Oncology & Carcinogenesis, 3211 Oncology and carcinogenesis, 3214 Pharmacology and pharmaceutical sciences

Abstract:

OBJECTIVE: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease. METHODS: The CAP-regimen consisted of cyclophosphamide 600 mg/m2, adriamycin 45 mg/m2, and cisplatin 50 mg/m2 administered intravenously on day one every 28 days. RESULTS: Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial. Fourteen patients had FIGO stage III, and ten had stage IV disease. The median number of CAP cycles was six. Ten patients had a complete and six had a partial response (response rate: 67%, 95% confidence limits: 45-84%). WHO grade III-IV side-effects included haematological toxicity, nausea/vomiting and alopecia. Furthermore, mild signs of cisplatin-related peripheral neurotoxicity were observed. At a median follow-up of 40 months, nine patients were alive and 15 had died due to malignant disease. The median time to progression was 13 months for all patients. The median overall survival was 24 months and the 1-, 3- and 5-year survival and their 95% confidence limits were 73% (54-92%), 25% (4-46%) and 19% (0-38%), respectively. CONCLUSION: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma. The response rate is moderate and the toxicity profile is acceptable.